Safety and antimicrobial resistance of mass administration of azithromycin in 1–11-month-old children in Nigeria. A project working to reduce infant mortality across Nigeria.
Description
SARMAAN is a hybrid Implementation Science project aimed at improving child survival and helping to fast-track the attainment of Sustainable Development Goal (SDG) 3 in Nigeria.
The project entails the mass drug administration of azithromycin to children aged 1–11months in communities with high infant mortality rates greater than 60 per 1000 live births, and continuous monitoring of safety and antimicrobial resistance patterns among 1–11-month-old children in Nigeria.
Furthermore, the project is generating vital information on the cost, cost-effectiveness, feasibility, and acceptability of using different platforms: Neglected Tropical Disease-Trachoma (NTD-Trachoma), National Program of Immunization (NPI), Polio Elimination Initiative (PEI) and the Seasonal Malaria Chemoprophylaxis (SMC) Platforms, to guide scale-up and policy in the country.
Study location
The project is currently being implemented in Abia, Akwa-Ibom, Kano, Kebbi, Jigawa and Sokoto regions.
Project duration
2022–2024
Investigators
Prof. Oliver Ezechi, Dr Abideen Salako, Dr. Adesola Z. Musa, Dr. Ifeoma Idigbe, Dr. Tajudeen Bamidele, Dr. Babatunde Adewale, Dr. Muinah Fowora, Dr. David Oladele, Dr. Kazeem Osuolale, Dr. Emelda Chukwu, Dr. Olusola Ajibaye, Dr. Bolorunduro Davies, Dr. Ebiere Hebertson, Dr. Agatha David, Prof. Arianna R. Means
Partners
Federal Ministry of Health Nigeria
Nigerian Institute of Medical Research (NIMR)
National Primary Healthcare Agency
Sightsavers
eHealth Africa
Speak Up Africa
University of Washington
